Vulvar Cancer

CR1525MK - Advance Solid Tumor – Pembrolizumab 
Study drug: Pembrolizumab 200 mg intravenously every 3 weeks (Q3W)
Main Inclusion criteria:

  • Any advanced solid tumor which is Microsatellite Instability (MSI)-High (MSI-H)
  • There is no limit to the number of prior treatment regimens
  • Can supply tumor tissue for study analyses 

Main Exclusion criteria:

  • Active autoimmune disease that has required systemic treatment in the past 2 years
  • Previously participated in any other pembrolizumab (MK-3475) study, or received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-Ligand 1 (anti-PD-L1), anti-PD-L2

CA209-848 Solid Tumors of High Tumor Mutational Burden (TMB-H)  Nivolumab +/- Ipilimumab
Main Inclusion Criteria:

  • Solid malignant tumor with TMB-H
  • Available tumor tissue and blood for TMB testing 
  • Measurable disease 

Main Exclusion Criteria:

  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody

CAPTUR (Canadian Profiling and Targeted Agent Utilization Trial)
Study Drug: targeted therapies
Main Inclusion Criteria: (screening step - non-drug specific)

  • Tumour genomic or protein expression testing
  • Patients must have measurable disease
  • ECOG performance status 0-2.

Main Exclusion criteria:

  • Patients who do not meet drug-specific eligibility requirements for the drug selected by the treating physician

Page last updated on 

We always seek feedback to make our site better.